Aptorum Group Ltd (APM)
NGM: APM
· Echtzeitkurs · USD
0.70
n/a (n/a)
Zum Schluss: Aug 16, 2026, 2:07 AM
Aptorum Group Ltd (APM) Stock Price, Analysis & Data
Keine Daten verfügbar
| Geld | 0.5 |
| Marktkapitalisierung | 570.06K |
| Umsatz (TTM) | n/a |
| Nettogewinn (TTM) | -1.36 Mio |
| Beta | 0.17 |
| EPS (ttm) | -1.9 |
| KGV (TTM) | n/a |
| Forward-KGV | -0.99 |
| KBV (TTM) | 0.02 |
| KUV (TTM) | n/a |
| Earnings Date | n/a |
| Brief | 0.83 |
| Volumen | 195,145 |
| Ø Vol. (20D) | 81,270 |
| Eröffnung | 0.70 |
| Vortagesschluss | n/a |
| Tagesspanne | 0.60 - 0.74 |
| 52-Wk Range | 0.60 - 44.70 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über APM
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the t...
Branche Biotechnology
Sektor Healthcare
IPO Datum Jul 17, 2026
Mitarbeiter 1
Börse NGM
Tickersymbol APM
Website https://www.aptorumgroup.com
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Aptorum Ltd 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -1.36 Mio, ein Rückgang von -68.06 %.
Finanzberichte
